Newsroom
Newsroom
Company announcements, scientific presentations and regulatory milestones.
Press release18 June 2026
Veltara doses first patient in Phase 2 study of VLT-201 in ulcerative colitis
The randomised, double-blind study will evaluate mucosal healing at week 12 across approximately 180 patients.
Publication2 April 2026
Veltara scientists publish single-cell atlas of inflamed intestinal tissue
The dataset describes immune cell states across 214 patient biopsies and is available to the research community.
Press release21 January 2026
Veltara completes $145 million Series C financing
Proceeds will fund the Phase 2 program for VLT-201 and advance two discovery candidates toward IND.